Glioblastoma is a rare and aggressive brain tumour with very limited treatment options, and far too little progress. At Yamicc, we work to change that: for patients and their loved ones, hope and time is everything.
As part of our mission in finding more effective treatments for rare cancers, we support the ReDiReCCT-GB trial. This trial focuses on personalized treatments and drug repurposing for glioblastoma patients. By gathering all sorts of data from the start, we hope to find new clinical insights and eventually more effective treatment options faster. Together, we can help accelerate new options for those who need them most.
